Os Therapies INC S-1 registration statements

OS Therapies Incorporated filed an S-1 registration statement to allow selling stockholders to resell up to 3.76 million common shares issued from a recent warrant exercise inducement, which generated over $4.2 million in gross proceeds for the company.

OS Therapies Incorporated has filed an S-1 registration statement to allow selling stockholders to resell up to 7.5 million shares, following positive Phase IIb clinical trial results for its lead Osteosarcoma drug candidate, OST-HER2, and the strategic acquisition of new immune-oncology assets.

OS Therapies is registering for resale up to 10.8 million common shares, representing securities issuable from a recent private placement involving convertible preferred stock and warrants.

OS Therapies aims to register the resale of up to $15 million in common stock through an equity line of credit, alongside commitment shares.

OS Therapies Incorporated has filed an amendment to its registration statement for the resale of up to $15 million in common stock through an equity line of credit with Square Gate Capital Master Fund, LLC.

OS Therapies has filed a registration statement for the resale of up to $15 million in common stock by Square Gate Capital Master Fund, LLC, following an equity line of credit agreement.

OS Therapies Incorporated is seeking to raise capital through an initial public offering to further the development of its cancer treatment pipeline, including OST-HER2 and OST-tADC.

OS Therapies enacts a 1-for-2 reverse stock split of its common stock as a strategic move prior to its initial public offering.

OS Therapies Incorporated has filed an S-1 registration statement for an initial public offering, seeking to fund the development of its Osteosarcoma and solid tumor treatments.

OS Therapies Incorporated files an amendment to its Form S-1 registration statement for a proposed $11.5 million initial public offering and the resale of shares by selling stockholders.